Literature DB >> 23774392

Interpretation of anti-ALK immunohistochemistry results.

Kengo Takeuchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23774392     DOI： 10.1097/JTO.0b013e318293e1ff

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

Review 1.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

2.  Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients.

Authors:  Anna Grenda; Bożena Jarosz; Paweł Krawczyk; Tomasz Kucharczyk; Kamila Wojas-Krawczyk; Katarzyna Reszka; Kinga Krukowska; Marcin Nicoś; Juliusz Pankowski; Maciej Bryl; Rodryg Ramlau; Barbara Kuźnar-Kamińska; Tomasz Grodzki; Aleksandra Szczęsna; Krystyna Siemiątkowska; Justyna Szumiło; Halina Batura-Gabryel; Michał Palonka; Janusz Milanowski
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).

Authors:  K Takeuchi; Y Togashi; Y Kamihara; T Fukuyama; H Yoshioka; A Inoue; H Katsuki; K Kiura; K Nakagawa; T Seto; M Maemondo; T Hida; M Harada; Y Ohe; N Nogami; N Yamamoto; M Nishio; T Tamura
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

4.  Novel ALK-specific mRNA in situ hybridization assay for non-small-cell lung carcinoma.

Authors:  Noriko Hirai; Takaaki Sasaki; Shunsuke Okumura; Masatoshi Sado; Naoko Akiyama; Masahiro Kitada; Hidehiro Takei; Yoshinobu Ohsaki
Journal:  Transl Lung Cancer Res       Date:  2020-04

5.  Case Report: A Pregnant Woman Diagnosed as ALK-Rearrangement Lung Large Cell Neuroendocrine Cancer With Brain Metastasis.

Authors:  Zaixiang Fu; Ganggui Zhu; Liquan Wang; Shen Hu; Lu Cheng; Fuyi Liu
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

6.  A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients.

Authors:  Kazuya Takamochi; Kengo Takeuchi; Takuo Hayashi; Shiaki Oh; Kenji Suzuki
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

7.  Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Authors:  Esther Conde; Ana Suárez-Gauthier; Amparo Benito; Pilar Garrido; Rosario García-Campelo; Michele Biscuola; Luis Paz-Ares; David Hardisson; Javier de Castro; M Carmen Camacho; Delvys Rodriguez-Abreu; Ihab Abdulkader; Josep Ramirez; Noemí Reguart; Marta Salido; Lara Pijuán; Edurne Arriola; Julián Sanz; Victoria Folgueras; Noemí Villanueva; Javier Gómez-Román; Manuel Hidalgo; Fernando López-Ríos
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

Review 8.  ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients.

Authors:  Hironori Uruga; Mari Mino-Kenudson
Journal:  Pharmgenomics Pers Med       Date:  2018-09-17

9.  Combined small cell lung carcinoma harboring ALK rearrangement: A case report and literature review.

Authors:  Takayuki Niitsu; Takayuki Shiroyama; Kotaro Miyake; Yoshimi Noda; Kansuke Kido; Reina Hara; Takatoshi Enomoto; Yuichi Adachi; Saori Amiya; Yasuhiko Suga; Kiyoharu Fukushima; Shohei Koyama; Kota Iwahori; Haruhiko Hirata; Izumi Nagatomo; Yoshito Takeda; Atsushi Kumanogoh
Journal:  Thorac Cancer       Date:  2020-10-25       Impact factor: 3.500
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.